MOSCOW, February 20 – RIA Novosti. The addition of Sputnik V vaccine components to Moderna and Pfizer vaccines will help them more effectively fight against coronavirus mutations, said Kirill Dmitriev, head of the Russian Direct Investment Fund.
“Yes, of course (ready to help – ed.),” Dmitriev said in an interview with the Russia 24 TV channel, answering the question whether the Sputnik V developers are ready to help Moderna and Pfizer.
“We believe that the addition of our component, including to the Pfizer vaccine and others, can more effectively fight mutations and, of course, this shows our openness and openness to all pharmaceutical companies. We believe that only working together can we really be most effective, “- said the head of the RDIF.
The developers of the Sputnik V vaccine earlier announced the start of studies on a combination of vaccines against COVID-19 – the Russian Sputnik V and the British AstraZeneca. Azerbaijan has previously issued a permit to conduct research on a combination of these vaccines.
Dmitriev on Saturday expressed the hope that it will also soon be approved in the Middle East.
The Sputnik V team has already suggested AstraZeneca and other developers, whose drugs are less than 90% effective, to use a combination of their vaccine and Sputnik V.
The scientific journal Lancet previously published the results of the third phase of clinical trials “Sputnik V”, confirming its high efficiency and safety. During phase III clinical trials, Sputnik V demonstrated high rates of efficacy, immunogenicity and safety – the vaccine efficacy was 91.6%. The vaccine provides complete protection against severe cases of the new coronavirus infection. Sputnik V has been approved for use in more than 30 countries.